Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0042963 (
vomiting
)
31,883
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Serotonin type 3 (5-HT
3
) receptors are ligand-gated ion channels formed by five subunits (5-HT3A-E), which are encoded by the HTR3A, HTR3B, HTR3C, HTR3D, and HTR3E genes. Functional receptors are pentameric complexes of diverse composition. Different receptor subtypes confer a predisposition to nausea and vomiting during chemotherapy, pregnancy, and following surgery. In addition, different subtypes contribute to neurogastroenterologic disorders such irritable bowel syndrome (IBS) and eating disorders as well as comorbid psychiatric conditions. 5-HT
3
receptor antagonists are established treatments for
emesis
and IBS and are beneficial in the treatment of psychiatric diseases. Several case-control and pharmacogenetic studies have demonstrated an association between HTR3 variants and psychiatric and neurogastroenterologic phenotypes. Recently, their potential as predictors of nausea and vomiting and treatment of psychiatric disorders became evident. This information is now available in the
serotonin receptor
3 HTR3 gene allelic variant database (www.htr3.uni-hd.de), which contains five sub-databases, one for each of the five different
serotonin receptor
genes HTR3A-E. Information on HTR3 variants, their functional relevance, associated phenotypes, and pharmacogenetic data such as drug response and side effects are available. This central information pool should help clinicians as well as scientists to evaluate their findings and to use the relevant information for subsequent genotype-phenotype correlation studies and pharmacogenetic approaches.
...
PMID:The Human Serotonin Type 3 Receptor Gene (HTR3A-E) Allelic Variant Database. 2776 4
Despite current advances in antiemetic treatments, between 30% to and 60% of oncology patients experience chemotherapy-induced nausea (CIN) and 13% to 33% report chemotherapy-induced
vomiting
(CIV). Inter-individual differences are observed in the occurrence and severity of chemotherapy-induced nausea and vomiting (CINV). This review summarizes and critiques studies on associations between occurrence and severity of CINV and polymorphisms in
serotonin receptor
, drug metabolism, and drug transport pathway genes. Sixteen studies evaluated the associations between the occurrence and/or severity of CINV and single nucleotide polymorphisms (SNPs). Across these studies, three SNPs in 5-hydroxytryptamine receptor (5-HT3R) genes, two alleles of the cytochrome P450 family 2 subfamily D member 6 (CYP2D6) gene, and three SNPs in ATP binding cassette subfamily B member 1 (ABCB1) gene were associated with the occurrence and severity of CINV. Given the limited number of polymorphisms evaluated, additional research is warranted to identify new mechanisms to develop more targeted therapies.
...
PMID:A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting. 2927 99
The serotonin 5-hydroxytryptamine 3 receptor (5-HT
3
R) plays a unique role within the seven classes of the
serotonin receptor
family, as it represents the only ionotropic receptor, while the other six members are G protein-coupled receptors (GPCRs). The 5-HT
3
receptor is related to chemo-/radiotherapy provoked
emesis
and dysfunction leads to neurodevelopmental disorders and psychopathologies. Since the development of the first
serotonin receptor
antagonist in the early 1990s, the range of highly selective and potent drugs expanded based on various chemical structures. Nevertheless, on-off-targeting of a pharmacophore's activity with high spatiotemporal resolution as provided by photopharmacology remains an unsolved challenge bearing additionally the opportunity for detailed receptor examination. In the presented work, we summarize the synthesis, photochromic properties and in vitro characterization of azobenzene-based photochromic derivatives of published 5-HT
3
R antagonists. Despite reported proof of principle of direct azologization, only one of the investigated derivatives showed antagonistic activity lacking isomer specificity.
...
PMID:Azologization of serotonin 5-HT
3
receptor antagonists. 3099 26
Nausea and vomiting are a persistent burden on cancer patients undergoing antineoplastic therapy, and adherence to guideline-specific prophylactic therapy is essential to minimise the risk. Nausea is more challenging to prevent than
vomiting
. This review summarises the choices of relevant drugs. Olanzapine is effective against nausea, but sedation can be a problem. There seems to be no major differences in effect or tolerability between different
serotonin receptor
antagonists and different neurokinin receptor antagonists. Consequently, the choice of drug should be based on price, risk of interactions and simple administration.
...
PMID:[Nausea and vomiting induced by antineoplastic therapy]. 3126 40
<< Previous
1
2
3
4
5
6